T cells are supposed to be relentless. These white blood cells patrol the body, identify threats, and destroy them.

A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer treatment without chemotherapy.

The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...

Engineers at the University of Pennsylvania have developed a new type of lipid nanoparticle (LNP) that could one day serve as a universal immunotherapy for cancers that form solid tumors, including ...

UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, ...

The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.

Chimeric antigen receptor (CAR) T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and other blood cancers. But researchers have ...

CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, which account for more than 85% of all cancers. Columbia University ...

Cbio A/S today announced that it has received regulatory clearance to begin a first-in-human Phase I/IIa clinical trial of novoleucel, the company’s next-generation T-cell therapy designed to improve ...